12:33 PM EDT, 10/17/2025 (MT Newswires) -- ZYUS Life Sciences ( ZLSCF ) on Friday received a $1.5-million loan from an independent director of the company.

The loan, which will be secured by the parent company's assets, holds an interest rate of 12% per year and will mature on Oct.31, 2027. The lender also agreed to advance an extra $0.5 million by Oct.31 under the same terms.

Additionally, 2.17-million two-year warrants to buy a share for $0.69 will be issued to the director involved in the loan, which holds an expiry date of two years.

Proceeds from the loan will be used for working capital needs, including the advancement of its clinical research activities pertaining to its Phase 2 UTOPIA clinical trial for its lead drug candidate Trichomylin Sofgel capsules.

Shares of ZYUS Life Sciences ( ZLSCF ) were last seen down $0.01 to $0.68 on the TSX Venture Exchange.

Price: 0.68, Change: -0.01, Percent Change: -1.45